查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404948

腫瘤臨床試驗市場規模、佔有率和趨勢分析報告：按階段類型、研究設計、地區和細分市場進行預測（2023-2030）

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Region, & Segment Forecasts, 2023-2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

腫瘤臨床試驗市場成長與趨勢：

預計2030年，全球腫瘤臨床試驗市場規模將達到194.9億美元，2023年至2030年複合年成長率為5.2%。

肺癌是全球癌症相關死亡的主要原因，美國每年估計有 180 萬人被診斷出肺癌，大約有 60,000 例新診斷的腎細胞癌病例，使癌症患者的生活變得更加困難。預計人數增加。此外，它還反映了癌症盛行率的不斷上升以及對有效癌症治療的需求不斷增加。

聯邦政府在資助和組織腫瘤學臨床研究方面發揮重要作用。 NCI 資助了美國近一半的腫瘤臨床試驗，並且 II 期試驗的數量不斷增加，導致市場成長。此外，根據藥品保健產品監管局 (MHRA) 的數據，2018 年至 2022 年間，II 期和 III 期申請增加了 5.5%。 IQVIA 於 2019 年 9 月宣布與癌症研究人員建立合作關係，以加強真實世界資料的使用並擴大腫瘤學臨床研究。

腫瘤臨床試驗市場報告亮點

  • 按階段類型分類，III 期細分市場預計在預測期內將以 5.6% 的複合年成長率成長最快。第三期的佔有率很高，因為雖然它是最昂貴的，但涉及的科目較多。第三階段涉及註冊和上市後承諾的長期安全研究。
  • 從試驗設計來看，介入試驗部分在 2022 年佔據最大的收益佔有率，達到 87.5%。腫瘤臨床試驗領域的介入試驗設計主要是由這些疾病的獨特挑戰所驅動的。
  • 由於該地區完善的藥品和藥物檢測法規，北美在 2022 年以 41.8% 的銷售佔有率佔據市場主導地位。由於中國和印度等新興經濟體開拓的商機，預計亞太地區在預測期內將以 7.1% 的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章腫瘤臨床試驗市場變數與趨勢

  • 市場動態
    • 市場促進因素影響分析
    • 市場抑制因素影響分析
    • 市場機會影響分析
    • 市場問題的影響分析
  • 產業分析工具
    • 波特的分析
    • 宏觀經濟分析

第4章腫瘤臨床試驗市場：階段類型分析

  • 相型波動分析及市場佔有率（2022/2030）
  • 按階段
  • 階段型市場規模、預測與趨勢分析（2018-2030）
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第5章腫瘤臨床試驗市場：研究設計分析

  • 研究設計變異分析與市場佔有率（2022/2030）
  • 透過研究設計
  • 研究設計市場規模、預測與趨勢分析（2018-2030）
    • 侵擾性的
    • 觀察性的
    • 延長訪問試用期

第6章腫瘤臨床試驗市場：區域估計與趨勢分析

  • 腫瘤臨床試驗市場：區域展望
  • 北美洲
    • 北美腫瘤臨床試驗市場估計與預測（2018-2030）
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭分析

  • 企業競爭形勢
  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • AstraZeneca
    • Merck & Co., Inc
    • IQVIA Inc
    • Gilead Sciences, Inc
    • F. Hoffmann-La Roche Ltd
    • PAREXEL International Corporation
    • PRA Health Sciences
    • Medpace
    • Pivotal

第8章分析師的觀點

Product Code: GVR-4-68039-139-7

Oncology Clinical Trials Market Growth & Trends:

The global oncology clinical trials market size is expected to reach USD 19.49 billion by 2030, registering a CAGR of 5.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. The number of people living with cancer is predicted to rise as lung cancer is the largest cause of cancer-related deaths worldwide, with an estimated 1.8 million people diagnosed and around 60,000 new cases of renal cell carcinoma diagnosed in the U.S. each year. Furthermore, it reflects an increasing prevalence of cancer and an increasing demand for efficient cancer treatment.

The federal government plays a huge role in funding and organizing clinical research in oncology. NCI funds nearly half of all cancer trials in the U.S., and there's a growing number of studies in phase II, leading to market growth. Moreover, according to the Medicines Healthcare Products Regulatory Agency (MHRA), between 2018 and 2022, the application for phase II and phase III trials increased by 5.5%. IQVIA announced a relationship with Cancer Researchers in September 2019 to enhance the use of real-world data and expand clinical research in oncology.

Oncology Clinical Trials Market Report Highlights:

  • Based on phase type, the phase III segment is expected to grow at the fastest CAGR of 5.6% during the forecast period. Phase III segment includes the high share of phase III trials, which is attributed to the fact that phase III trials are the most expensive but involve many subjects. Long-term safety studies are conducted for registration and post-marketing commitments in phase III trials
  • Based on study design, the interventional studies segment accounted for the largest revenue share of 87.5% in 2022. The driving factors for interventional study design in the oncology clinical trials sector primarily revolve around these conditions' unique challenges
  • North America dominated the market with a revenue share of 41.8 % in 2022 owing to the well-established pharmaceutical and drug trials regulations in the region. Asia Pacific is anticipated to grow at the fastest CAGR of 7.1% over the forecast period due to the presence of untapped opportunities in the emerging economies of China and India

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3

Chapter 2 Executive Summary

  • 2.1 Market Outlook
    • 2.1.1 Regional Insights
    • 2.1.2 Competitive Landscape
  • 2.2 Market Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Segment Snapshot
  • 2.5 Competitive Landscape

Chapter 3 Oncology Clinical Trials Market Variables and Trends

  • 3.1 Market Dynamics
    • 3.1.1 Market driver impact analysis
      • 3.1.1.1 Increasing prevalence of Cancer
      • 3.1.1.2 Rise in the number of CROs for conducting research activities
    • 3.1.2 Market restraint impact analysis
      • 3.1.2.1 High cost associated with oncological clinical trial
    • 3.1.3 Market Opportunities impact analysis
      • 3.1.3.1 Technological Advancements
    • 3.1.4 Market challenges impact analysis
      • 3.1.4.1 Strict regulations for patient enrollment in clinical trials
  • 3.2 Industry Analysis Tools
    • 3.2.1 Porter's analysis
    • 3.2.2 Macroeconomic analysis

Chapter 4 Oncology Clinical Trials Market: Phase Type Analysis

  • 4.1 Type Movement Analysis & Market Share, 2022 & 2030
  • 4.2 Oncology Clinical Trials Market Estimates & Forecast, By Phase (USD Million)
  • 4.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Type
    • 4.3.1 Phase I
      • 4.3.1.1 Phase I market, 2018 - 2030 (USD Million)
    • 4.3.2 Phase II
      • 4.3.2.1 Phase II market, 2018 - 2030 (USD Million)
    • 4.3.3 Phase III
      • 4.3.3.1 Phase III market, 2018 - 2030 (USD Million)
    • 4.3.4 Phase IV
      • 4.3.4.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 5 Oncology Clinical Trials Market: Study Design Analysis

  • 5.1 Study Design Movement Analysis & Market Share, 2022 & 2030
  • 5.2 Oncology Clinical Trials Market Estimates & Forecast, By Study Design (USD Million)
  • 5.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Study Design
    • 5.3.1 Interventional
      • 5.3.1.1 Interventional market, 2018 - 2030 (USD Million)
    • 5.3.2 Observational
      • 5.3.2.1 Observational market, 2018 - 2030 (USD Million)
    • 5.3.3 Expanded access trials
      • 5.3.3.1 Expanded Access market, 2018 - 2030 (USD Million)

Chapter 6 Oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1 Oncology Clinical Trials Market: Regional Outlook
  • 6.2 North America
    • 6.2.1 North america oncology clinical trials market estimates & Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key country dynamics
      • 6.2.2.2 U.S. oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Key country dynamics
      • 6.2.3.2 Canada oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3 Europe
      • 6.3.1.1 Europe oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 Key country dynamics
      • 6.3.2.2 UK oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Key country dynamics
      • 6.3.3.2 Germany oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 Key country dynamics
      • 6.3.4.2 France oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Key country dynamics
      • 6.3.5.2 Italy oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Key country dynamics
      • 6.3.6.2 Spain oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.7 Sweden
      • 6.3.7.1 Key country dynamics
      • 6.3.7.2 Sweden oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8 Denmark
      • 6.3.8.1 Key country dynamics
      • 6.3.8.2 Denmark oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9 NORWAY
      • 6.3.9.1 Key country dynamics
      • 6.3.9.2 Norway oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4 ASIA Pacific
      • 6.4.1.1 Asia Pacific oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key country dynamics
      • 6.4.2.2 Japan oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 Key country dynamics
      • 6.4.3.2 China oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 Key country dynamics
      • 6.4.4.2 India oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5 Australia
      • 6.4.5.1 Key country dynamics
      • 6.4.5.2 Australia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6 South Korea
      • 6.4.6.1 Key country dynamics
      • 6.4.6.2 South Korea oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7 Thailand
      • 6.4.7.1 Key country dynamics
      • 6.4.7.2 Thailand oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5 Latin America
      • 6.5.1.1 Latin America oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key country dynamics
      • 6.5.2.2 Brazil oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Key country dynamics
      • 6.5.3.2 Mexico oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Key country dynamics
      • 6.5.4.2 Argentina oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6 Middle East & Africa
      • 6.6.1.1 Middle East & Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 Key country dynamics
      • 6.6.2.2 South Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Key country dynamics
      • 6.6.3.2 Saudi Arabia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 Key country dynamics
      • 6.6.4.2 UAE oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5 Kuwait
      • 6.6.5.1 Key country dynamics
      • 6.6.5.2 Kuwait oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Competitive Landscape
  • 7.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2 Market Participant Categorization
    • 7.2.1 AstraZeneca
      • 7.2.1.1 Company overview
      • 7.2.1.2 Financial performance
      • 7.2.1.3 Phase benchmarking
      • 7.2.1.4 Strategic initiatives
    • 7.2.2 Merck & Co., Inc
      • 7.2.2.1 Company overview
      • 7.2.2.2 Financial performance
      • 7.2.2.3 Phase benchmarking
      • 7.2.2.4 Strategic initiatives
    • 7.2.3 IQVIA Inc
      • 7.2.3.1 Company overview
      • 7.2.3.2 Financial performance
      • 7.2.3.3 Phase benchmarking
      • 7.2.3.4 Strategic initiatives
    • 7.2.4 Gilead Sciences, Inc
      • 7.2.4.1 Company overview
      • 7.2.4.2 Financial performance
      • 7.2.4.3 Phase benchmarking
      • 7.2.4.4 Strategic initiatives
    • 7.2.5 F. Hoffmann-La Roche Ltd
      • 7.2.5.1 Company overview
      • 7.2.5.2 Financial performance
      • 7.2.5.3 Phase benchmarking
      • 7.2.5.4 Strategic initiatives
    • 7.2.6 PAREXEL International Corporation
      • 7.2.6.1 Company overview
      • 7.2.6.2 Financial performance
      • 7.2.6.3 Phase benchmarking
      • 7.2.6.4 Strategic initiatives
    • 7.2.7 PRA Health Sciences
      • 7.2.7.1 Company overview
      • 7.2.7.2 Financial performance
      • 7.2.7.3 Phase benchmarking
      • 7.2.7.4 Strategic initiatives
    • 7.2.8 Medpace
      • 7.2.8.1 Company overview
      • 7.2.8.2 Financial performance
      • 7.2.8.3 Phase benchmarking
      • 7.2.8.4 Strategic initiatives
    • 7.2.9 Pivotal
      • 7.2.9.1 Company overview
      • 7.2.9.2 Financial performance
      • 7.2.9.3 Phase benchmarking
      • 7.2.9.4 Strategic initiatives

Chapter 8 Analyst Perspective

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 3 North America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 4 North America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 5 U.S. oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 6 U.S. oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 7 Canada oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 8 Canada oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 9 Europe oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 10 Europe oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 11 Europe oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 12 Germany oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 13 Germany oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 14 UK oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 15 UK oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 16 France oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 17 France oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 18 Italy oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 19 Italy oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 20 Spain oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 21 Spain oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 22 Sweden oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 23 Sweden oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 24 Norway oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 25 Norway oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 26 Denmark oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 27 Denmark oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 28 Asia Pacific oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 29 Asia Pacific oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 30 Asia Pacific oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 31 China oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 32 China oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 33 Japan oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 34 Japan oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 35 India oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 36 India oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 37 Australia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 38 Australia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 39 Thailand oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 40 Thailand oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 41 South Korea oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 42 South Korea oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 43 Latin America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 44 Latin America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 45 Latin America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 46 Brazil oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 47 Brazil oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 48 Brazil oncology clinical trials market, by application, 2018 - 2030 (USD million)
  • Table 49 Mexico oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 50 Mexico oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 51 Argentina oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 52 Argentina oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 53 Middle East and Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 54 Middle East and Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 55 Middle East and Africa oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 56 South Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 57 South Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 58 Saudi Arabia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 59 Saudi Arabia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 60 UAE oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 61 UAE oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 62 Kuwait oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 63 Kuwait oncology clinical trials market, by study design, 2018 - 2030 (USD million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Oncology clinical trials: Market outlook
  • Fig. 9 Oncology clinical trials: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Oncology clinical trials market driver impact
  • Fig. 15 Oncology clinical trials market restraint impact
  • Fig. 16 Oncology clinical trials market strategic initiatives analysis
  • Fig. 17 Oncology clinical trials market: Type movement analysis
  • Fig. 18 Oncology clinical trials market: type outlook and key takeaways
  • Fig. 19 Phase I market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Phase II market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Phase III market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Phase IV market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Oncology clinical trials market: study design movement analysis
  • Fig. 25 Oncology clinical trials market: study design outlook and key takeaways
  • Fig. 26 Interventional studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 27 Observational studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 Expanded access studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Global oncology clinical trials market: Regional movement analysis
  • Fig. 30 Global oncology clinical trials market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)